



PATENT
Docket No. 229752000700
Client Reference 2178670/EJH/aal

CERTIFICATE OF HAND DELIVERY

I hereby certify that this correspondence is being hand filed with the United States Patent and Trademark Office in Washington, D.C. on February 8, 2002.


Barry C. Kinney

RECEIVED
FEB 14 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

ZIMMET, Paul Zev

Serial No.: 09/331,930

Filing Date: June 30, 1999

For: A NOVEL GENE AND USES
THEREFOR

Examiner: J. Seharaseyon

Group Art Unit: 1647

14/B
M.G.J
2/27/02

AMENDMENT UNDER 37 C.F.R. §1.111

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This is in response to the Office Action dated August 8, 2001, please amend this application as follows.

IN THE SPECIFICATION

Please amend the title of this application to "Gene for the Modulation of Obesity, Diabetes, and Metabolic Energy Levels".

IN THE CLAIMS

Please cancel Claims 2, 4, and 7-19 without prejudice or disclaimer.



Claims 1-6 have been rejected under 35 USC 112, first paragraph. Since the pending claims, as amended, are fully supported by the original specification, this rejection is also moot and should be withdrawn.

Claim 2 has been rejected under 35 USC 102(a) as being anticipated by Pauley et al. Since claim 2 has been cancelled, this rejection has been obviated. Applicants note, however, that Pauley does not disclose the expression of the molecule of any currently pending claim in larger amounts in the hypothalamus tissue of obese animals compared to lean animals. Moreover, the reference fails to provide any functional information regarding the sequence.

Claim 3 has been rejected under 35 USC 102(a) as being anticipated by Marra et al. Although the amendment to claim 3 presented herein obviates this rejection, applicants respectfully encourage the Examiner to consider that the sequence disclosed by Marra fails to disclose the expression of the molecule in larger amounts in the hypothalamus tissue of obese animals compared to lean animals.

Finally, claim 1 has been rejected under 35 USC 102(b) as being anticipated by Wilding et al. In view of the amendment to claim 1, this rejection is now moot.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version with markings to show changes made**".

